'On consolidated basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Sanofi India has increased 6.79% to Rs 524 crore. Operating profit margin has declined from 23.13% to 22.84%, leading to 5.46% rise in operating profit to Rs 119.70 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 11.20% to 16.66%. Purchase of finished goods cost fell from 53.82% to 36.11%. Employee cost increased from 9.94% to 10.14%. Other expenses rose from 9.26% to 15.67%.
Other income fell 78.30% to Rs 2.3 crore. PBIDT fell 1.69% to Rs 122 crore. Provision for interest rose 33.33% to Rs 0.4 crore.
PBDT fell 1.78% to Rs 121.6 crore. Provision for depreciation fell 2.17% to Rs 9 crore.
Profit before tax down 1.75% to Rs 112.60 crore...
Pleaselogin & subscribe to view the full report.
More Reports
-
(01-Mar-2025)
Foseco India
-
Maintains double digit revenue growth and stable OPM
-
(28-Feb-2025)
Sanofi India
-
Net up 33% largely on higher sales, higher OI and lower taxation
|
|